Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001329358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
4/03/2026
Date registered
Help: Date registered
4/11/2026
Date last updated
Help: Date last updated
4/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Better matching care to the needs of patients with musculoskeletal pain: the MATCH trial
Scientific title
Matching a multidisciplinary management strategy to patients with chronic musculoskeletal pain (MATCH): an internal pilot and feasibility stepped-wedge cluster randomised controlled trial
Additional trial identifiers [1] 317745 0
UQCTC-021
Additional trial identifiers [2] 317746 0
MRF2044293
Universal Trial Number (UTN)
Trial acronym
MATCH
Related trial records

Health condition
Health condition(s) studied:
Musculoskeletal conditions 339121 0
Condition category
Condition code
Musculoskeletal 335409 335409 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
What is the intervention
The MATCH intervention is a co-designed (patients, clinicians) service improvement strategy to better match care to patients’ needs and better engage patients in care offered by Queensland Health’s Musculoskeletal Physiotherapy Screening Clinic and Multidisciplinary Service (MPSC&MDS). It includes 4 components to systematically address previously identified barriers to matching care to patients needs and engaging them in that care:
1. The MATCH MDT Clinical Indicators have been developed by the service’s Multidisciplinary teams (MDT) disciplines via the discipline specific focus groups and codesign team. These new indicators comprise a set of statements to guide the Advanced Musculoskeletal Physiotherapist (AMP) decisions regarding patient referral to each MDT member.

In current usual care (UC), AMP clinicians make decisions regarding patient referral/s to MDT disciplines at the initial consultation based on information gathered from routinely collected patient questionnaires in addition to information from their patient examination (patient interview and physical examination). In MATCH, this same process will continue but referral decisions will be supported by AMP clinicians routinely considering the Clinical Indicator statements to more systematically guide referral to MDT disciplines. Specifically, AMP clinicians will be trained to firstly select which Clinical Indicators are relevant for a patient for each specific discipline (indicated by ticking the box next to each indicator). Then based on the presence and perceived priority of the identified indicators, AMP’s and patients will collaboratively make decisions regarding referral to MDT disciplines. Thus, while referral decisions are still based on informed clinical judgement, these indicators provide a more systematic approach for AMPs to consider the most relevant indicators when decision making regarding MDT referrals.

2. The MATCH Digital Information Hub will be accessible visually (no log in) for patients as a website directly following acceptance of their referral to the service. It will provide comprehensive yet simply presented information in written and video form regarding the service, its purpose, information regarding the role of the AMP in the service and the role of the MDT clinicians. The aim of the digital information hub is to leverage the time before the patient physically enters the service to address patients concerns, questions and reduce uncertainties about the service. The intent of this information hub is to empower patients in shared decision-making at the first appointment by providing prior knowledge of the roles of the different MDT members, and to reduce perceptions of stigma associated with referral to some disciplines (e.g. dietetics and psychology). It is also intended as an initial communication strategy to help set realistic patient expectations of the service and encourage patients to engage with their clinical management in the service.

3. The MATCH Patient Roadmap is a personalised roadmap of the patient’s journey through the service that can be progressively personalised by patients with support of the MPSC&MDS clinicians. In this manner it will act as a shared roadmap, a vehicle and time map, for collaborative patient goal-setting, MDT care scheduling, facilitating best practice and consistent messaging. This addresses the inconsistent messaging and approach to goal-setting identified in our previous survey and focus groups. The roadmap will be a document that is owned by the patient and will be their responsibility to take it to MDT appointments so that all MPSC&MDT clinicians have access to it and progressively modify it as appropriate.

4. The MATCH Contact Person will empower and inform patients, their contact details will be available should the patient require further guidance about the service or their care in addition to that provided by the digital information hub, both before and during their period of care in the service.

How, where and for how long is the intervention being delivered?
The control and intervention period in the MATCH Pilot and Feasibility RCT will run for a total of 12 months (1 February 2027- 31 January 2028). This includes the following 3 components:
- Usual Care (UC) control phase
- Training and Implementation (T&I) phase
- The MATCH intervention (MAT) phase
Four MPSC&MDS sites will participate in the pilot and feasibility trial. All four sites will simultaneously commence with a UC control phase, then based on random allocation to the timing of the switch, will switch to 6 weeks of MATCH T&I, with 2 sites switching after the first 6 weeks and the next 2 sites switching after the first 12 weeks. Post MATCH T&I, sites will offer MATCH (MAT). Outcomes will be recorded for patients entering the service in all phases, with all patients undergoing a 6-month follow-up period after their entry to the service (MATCH Patient Questionnaire – 6 months).
Implementation of MATCH is underpinned by a multicomponent MATCH implementation strategy and a MATCH training program for MPSC&MDS clinicians and administrative staff at each site. The MATCH implementation strategy was developed using an Implementation Research Logic Model, which identified implementation determinants and associated strategies guided by the Consolidated Framework for Implementation Research matching tool. This multicomponent implementation strategy will be adopted to support behaviour change in clinicians and patients to enhance uptake of MATCH resources and participate in MATCH training. The MATCH implementation plan has the following components:
1. Assessment of site readiness: During the T&I phase and prior to commencing the MATCH implementation, service staff (AMP’s) at each site will complete the MATCH NoMAD Survey to identify key local context risks associated with embedding MATCH at their site. This will be completed prior to attending training/education sessions. Risk mitigation strategies will be discussed as part of training/education if needed prior to commencement.

2. Educational seminars in the use of the new systematic MATCH clinical indicators and decision flow chart processes and resources, developed and delivered by the research team. These education seminars will be offered in a group setting, face-to-face, on multiple occasions at each hospital site throughout the 6-week T&I implementation period in protected continuing professional development time. All members of the service team within each site will be invited to participate and participation in the education seminars will be monitored, with reminders sent and personal communication from the research team as needed.

3. MATCH Implementation Champions are a key feature of the implementation strategy as they will work with the research team to reinforce changes and the uptake of MATCH, inform local opinion leaders on MATCH progress, provide support for troubleshooting with clinicians and facilitate local discussions and learning collaboratives. Experienced MPSC&MDS clinicians from the service will be invited to become MATCH Implementation Champions (1 per site), to champion MATCH with their clinician colleagues and local opinion leaders, embed MATCH within usual scheduled team or individual meetings, take a leadership role in coordinating and facilitating learning collaboratives with research team support, and provide personal feedback and refresher sessions via one-to-one or small group workshops as needed in the course of usually scheduled team or individual meetings.

4. Learning collaboratives whereby audio-recordings of clinician-patient consultations (with consent) before and after training (described above), simulated patient scenarios using MATCH, as well as scripted conversations and role-play practice will stimulate reflexivity in clinician practice.

5. Integration of Patient resources in the form of the digital online hub, roadmap and contact person will be a priority in the implementation plan. Site administrative processes will be prioritised ensuring patients have access to these online resources immediately following triaging to the MPSC&MDS service so that patients can have access prior to them physically entering the service.

Adherence (eg. Reminders, monitoring)
All members of the service team within each hospital site will be invited to attend and participate in training and implementation activities. A training log will be kept of attendance at training sessions, and reminders will be sent to staff members as needed.
The University of Queensland’s Clinical Trial Centre is responsible for oversight of trial quality, and will implement proportionate, system-level and record-level verification using centralised, risk-based methods to ensuring compliance at sites. This will ensure that the trial is conducted, recorded and reported as per the trial protocol via a combination of both remote and onsite monitoring visits (if required).
Intervention code [1] 333347 0
Behaviour
Description of the comparator or control
Each of the 4 sites commences with a period of usual care in this stepped wedge cluster trial, then based on random allocation to the timing of the switch, will switch to 6 weeks of MATCH training and implementation (T&I), with 2 sites switching after the first 6 weeks and the next 2 sites switching after the first 12 weeks. Post-switch, sites will continue to offer MATCH (MAT) following their training phase. Outcomes will be recorded and compared for patients entering the service before implementation during the UC phase, during the training and implementation phase (T&I), and after the implementation phase (MAT), with 6 month follow-up after entry to the service.
Control group
Active

Outcomes
Primary outcome [1] 344576 0
Intervention Fidelity
Timepoint [1] 344576 0
All measures will be recorded up to 6 months post-implementation phase.
Primary outcome [2] 346854 0
Patient Engagement with the service
Timepoint [2] 346854 0
All measures will be recorded up to 6 months post-implementation phase.
Primary outcome [3] 346856 0
Acceptability of MATCH to staff
Timepoint [3] 346856 0
All measures will be recorded up to 6 months post-implementation phase.
Secondary outcome [1] 458427 0
Additional Primary Outcome: Data Completion
Timepoint [1] 458427 0
6 months post-implementation
Secondary outcome [2] 458428 0
Clinical Outcome: feasibility of using the MSK-HQ to assess the effectiveness of MATCH
Timepoint [2] 458428 0
Initial and follow-up patient reported outcomes via questionnaire recorded at baseline and at 6-months post-implementation, respectively.
Secondary outcome [3] 468049 0
Economic Evaluation: Feasibility of using the EQ5D-5L to assess the effectiveness of MATCH
Timepoint [3] 468049 0
Initial and follow-up patient reported outcomes via questionnaire recorded at baseline and at 6-months post-implementation, respectively.
Secondary outcome [4] 468390 0
Implementation Outcome: MATCH Service implementation plan Adoption - Number and proportion of eligible staff accessing T&I components
Timepoint [4] 468390 0
During training and implementation (T&I) phase
Secondary outcome [5] 468391 0
Implementation Outcome: MATCH Service implementation plan Implementation Costs - What are the direct/indirect costs associated with T&I time and resources?
Timepoint [5] 468391 0
During training and implementation phase
Secondary outcome [6] 468398 0
Implementation Outcome: MATCH Service implementation plan Appropriateness - Do staff consider the multi-component implementation plan to be appropriate (e.g. relevant, useful, practical) for their preparation of MATCH?
Timepoint [6] 468398 0
Between 3-6 months after commencement of the MATCH (MAT) phase. Each participant will be invited to participate in one interview.
Secondary outcome [7] 468409 0
Implementation Outcome: MATCH Service implementation plan Fidelity - The extent to which the shared-decision making processes and communication strategies outlined during the T&I are carried out during clinical consultations.
Timepoint [7] 468409 0
During usual care (control period) and anytime during the MAT phase.
Secondary outcome [8] 468410 0
Implementation Outcome: MATCH Intervention Clinical Indicators Reach - The number and proportion of eligible patients where the clinical indicator checklist was completed
Timepoint [8] 468410 0
Cumulative data will be assessed at the conclusion of the MAT Phase.
Secondary outcome [9] 468411 0
Implementation Outcome: MATCH Intervention Clinical Indicators Fidelity - % of patients offered a referred to each MDT profession based on the clinical indicators listed.
Timepoint [9] 468411 0
Cumulative data will be assessed at the conclusion of the MAT Phase.
Secondary outcome [10] 468412 0
Implementation Outcome: MATCH Intervention Clinical Indicators Appropriateness - % of patients where the 'other' box has been ticked for each MDT where a referral was indicated. Are the clinical indicators considered appropriate/compatible within the local context to facilitate shared decision-making and matching care needs.
Timepoint [10] 468412 0
Cumulative data will be assessed at the conclusion of the MAT Phase. Staff interview data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [11] 468413 0
Implementation Outcome: MATCH Intervention Clinical Indicators Acceptability The extent to which the clinicians accept the clinical indicators, and the process of which it is operationalised.
Timepoint [11] 468413 0
Staff interview data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [12] 468414 0
Implementation Outcome: MATCH Intervention Clinical Indicators Feasibility - The ability to which the clinical indicators can be incorporated into the patient’s MPSC journey.
Timepoint [12] 468414 0
Staff interview data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [13] 468416 0
Implementation Outcome: MATCH Intervention Patient Roadmap Adoption - How has the roadmap been adopted throughout the patient’s MPSC journey?
Timepoint [13] 468416 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [14] 468417 0
Implementation Outcome: MATCH Intervention Patient Roadmap Fidelity - The extent to which the roadmap was completed/used as intended.
Timepoint [14] 468417 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [15] 468418 0
Implementation Outcome: MATCH Intervention Patient Roadmap Appropriateness - Is the roadmap considered appropriate/compatible within the local context to facilitate shared decision-making and matching care needs.
Timepoint [15] 468418 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [16] 468419 0
Implementation Outcome: MATCH Intervention Patient Roadmap Feasibility - Ability to incorporate roadmap into MPSC journey and clinical consultation.
Timepoint [16] 468419 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [17] 468420 0
Implementation Outcome: MATCH Intervention Patient Roadmap Acceptability - Is the roadmap seen as an acceptable intervention to support shared decision-making and matching care needs.
Timepoint [17] 468420 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [18] 468422 0
Implementation Outcome: MATCH Intervention Contact Person (CP) Reach - % eligible patients who chose to access CP support during their MPSC journey % of patients who choose to access CP support who proceed to get support from the CP (inclusive of number/type of consults, FTA%)
Timepoint [18] 468422 0
Cumulative data will be assessed at the conclusion of the MAT phase.
Secondary outcome [19] 468425 0
Implementation Outcome: MATCH Intervention Contact Person (CP) Implementation - Nature and extent of activities undertaken by the CP when compared to the 'role description'
Timepoint [19] 468425 0
Staff interview data completed between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [20] 468426 0
Implementation Outcome: MATCH Intervention Contact Person (CP) Acceptability - Acceptability of the CP role in patient MPSC journey
Timepoint [20] 468426 0
Staff interview data as well as the PREM-CP survey will be completed between 3-6 months after commencement of the MAT phase.
Secondary outcome [21] 468427 0
Implementation Outcome: MATCH Intervention Contact Person (CP) Appropriateness - Is the CP role considered appropriate/compatible within the local context to facilitate shared decision-making and matching care needs.
Timepoint [21] 468427 0
Staff interview data as well as the PREM-CP survey will be completed between 3-6 months after commencement of the MAT phase.
Secondary outcome [22] 468435 0
Implementation Outcome: MATCH Intervention Contact Person (CP) Sustainability - Service level indicators (referral activity, clinician engagement with the dedicated CP and proportion of eligible patients referred to CP) during the MAT intervention and follow-up period.
Timepoint [22] 468435 0
Cumulative data will be assessed at the conclusion of the MAT phase.
Secondary outcome [23] 468441 0
Implementation Outcome: MATCH Intervention Digital Resource Hub Appropriateness - Is the digital hub considered appropriate/compatible within the local context to facilitate shared decision-making and matching care needs.
Timepoint [23] 468441 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [24] 468442 0
Implementation Outcome: MATCH Intervention Digital Resource Hub Acceptability - The extent to which knowledge users accepted the digital hub as a resource that supported informed shared decision-making and minimised negative emotions throughout patient journey with MPSC.
Timepoint [24] 468442 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [25] 468443 0
Implementation Outcome: MATCH Intervention Digital Resource Hub Feasibility - The ability to which the digital hub can be incorporated into the patient’s MPSC journey.
Timepoint [25] 468443 0
Staff interview data as well as patient journey mapping data between 3-6 months after commencement of the MATCH (MAT) phase.
Secondary outcome [26] 468444 0
Implementation Outcome: MATCH Intervention Digital Resource Hub Implementation Cost Determine the one-off costs associated with the development and implementation (including hosting, maintenance and updating) of the digital hub.
Timepoint [26] 468444 0
Assessed at the conclusion of the overall study period.

Eligibility
Key inclusion criteria
Eligible MPSC&MDS Sites:
Queensland MPSC&MDS sites willing to undertake MATCH training and implementation, as well as participate in implementation outcome evaluation.

Eligible MPSC&MDS staff (AMP and MDT clinicians and Administrative Officers (AO)) are employed in the service to organise and provide episodes of care to patients entering the service from the initial assessment to the multidisciplinary care phase, through to review and discharge from the service. There are approximately 22 AMPs, 45 MDTs and 12 AOs who are eligible to participate across the 4 cluster sites in this pilot trial.

Eligible MPSC&MDS patients
Eligible patients will have been referred to orthopaedic or neurosurgical speciality services at the cluster site for management of their musculoskeletal (MSK) disorder and through standard care procedures have been triaged to be assessed/managed within the MPSC&MDS. Eligible participants are adults (aged 18 years or older) with chronic MSK pain who are offered non-surgical MDT management following their initial Screening Consultation with the AMP. Eligible patients will be identified from the routinely collected service data collated for all patients entering the service during the UC, T&I, and MAT phases of the trial (estimated to be approximately 458 patient cases overall, through a waiver of consent and Queensland Health Public Health Act (PHA) approval process.

Eligible MPSC&MDS patients for involvement in the process evaluation will be a purposively sampled subset of patients at each site (approx. up to 25 per site) who will be invited and recruited to maximise diversity of MSK condition, discipline of care received and patient characteristics.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria
MPSC&MDS Clinicians: There are no specific exclusion criteria for these participants.
Ineligible MPSC&MDS Patients: Cases for those patients with escalated surgical or medical review, or who are discharged from the service following screening will be ineligible to be included in this pilot and feasibility RCT.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
There is no concealment. All clusters (sites) will be informed that they will crossover to the MATCH intervention phase once the Usual Care Phase is complete at their site.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Within a group of 4 sites, two sites will be chosen to switch to offer MATCH after 6 weeks and 2 after 12 weeks. This will be decided by the study statistician with the help of random numbers.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size and statistical power
As this is an internal pilot and feasibility RCT, a sample size calculation based on a primary clinical outcome such as MSK health (MSK-HQ) is not appropriate. Using service data (2023/2024 financial year) we estimate approximately 3,991 new patients/year will enter the 4 clusters, or 1,835 patients over the 24-week pilot RCT recruitment period. Approximately 39% will be either discharged at the initial Screening Consultation or will not require review by the Service Leader, leaving 1,119 patients. At the initial Screening Consultation, we anticipate at least 41% will have clinical indicators for MDT care, which means our progression criteria, exploration of implementation outcomes and process evaluation can be evaluated with approximately 458 patient cases overall (172 in UC phase, 114 T&I phase, 172 in MATCH MOC phase). As data completeness is a progression criterion, the summary estimates and proportions of patients with MSK-HQ and EQ5D-5L data at baseline and 6 months follow-up will inform the future sample size calculation for the full RCT.

Service staff (22 AMPs, 45 MDTs and 12 AOs) across the sites will also provide data for outcomes as well as process evaluation for this study. To capture diversity between sites and roles (AMPs, MDTs, AOs) within the data all service staff from the participating sites will be offered participation so no sample size calculations were required.

Statistical methods
All data will be analysed and reported in accordance with the 2016 CONSORT Extension Statement for the reporting of pilot and feasibility RCTs and the guidance about reporting of stepped-wedge cluster RCTs using routinely collected data as well as the Standards for Reporting Implementation Studies (StaRI) statement.

Quantitative analysis: Progression criteria outcomes will be calculated by simply pooling data in the UC and MATCH MOC phases across all 4 clusters in the pilot RCT. Data from each cluster for each 6-week phase will also be reported. MSK-HQ and EQ5D-5L scores at baseline and 6 months will be summarised descriptively only (given this is a pilot and feasibility RCT) and considered alongside the minimum clinically important change threshold for the MSK-HQ outcome measure for individuals (ie. 6 point difference in MSK-HQ). Simple descriptive statistics will be used to describe other exploratory implementation outcomes.

Qualitative analysis
Analysis related to the Process Evaluation of the implementation of MATCH: Data from field notes of rapid ethnographic observations and audio-recordings of consultations will be analysed using a memo-writing and an audio-memoing approach to thematic analysis, respectively. Journey mapping data will be analysed using content analysis. Results from observations, audio-recordings and journey mapping from clusters 1 and 2 will be triangulated to inform T&I of clusters 3 and 4, and the results of all 4 clusters in the pilot RCT will help refine the MATCH training and implementation activities for the future full RCT.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/02/2027
Actual
Date of last participant enrolment
Anticipated
27/08/2027
Actual
Date of last data collection
Anticipated
28/01/2028
Actual
Sample size
Target
537
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29219 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [2] 29220 0
Toowoomba Hospital - Toowoomba
Recruitment hospital [3] 29221 0
Redland Hospital - Cleveland
Recruitment hospital [4] 29222 0
The Townsville Hospital - Douglas
Recruitment postcode(s) [1] 45527 0
4029 - Herston
Recruitment postcode(s) [2] 45528 0
4350 - Toowoomba
Recruitment postcode(s) [3] 45529 0
4163 - Cleveland
Recruitment postcode(s) [4] 45530 0
4814 - Douglas

Funding & Sponsors
Funding source category [1] 320121 0
Government body
Name [1] 320121 0
Funding source/government body - Medical Research Future Fund (MRFF), 2024 Novel Treatments and Management Strategies for Chronic Pain Grant. Grant Identification Number: MRF2044293
Country [1] 320121 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 322679 0
None
Name [1] 322679 0
Address [1] 322679 0
Country [1] 322679 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318669 0
Metro North Health Human Research Ethics Committee
Ethics committee address [1] 318669 0
Ethics committee country [1] 318669 0
Australia
Date submitted for ethics approval [1] 318669 0
25/03/2026
Approval date [1] 318669 0
26/06/2026
Ethics approval number [1] 318669 0
HREC/2026/MNH/121941
Ethics committee name [2] 321482 0
The University of Queensland Human Research Ethics Committee A
Ethics committee address [2] 321482 0
Ethics committee country [2] 321482 0
Australia
Date submitted for ethics approval [2] 321482 0
30/07/2026
Approval date [2] 321482 0
05/08/2026
Ethics approval number [2] 321482 0
2026/HE011539

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144870 0
Prof Shaun O'Leary
Address 144870 0
School of Health and Rehabilitation Sciences, University of Queensland, Building 84a Therapies Annexe, QLD 4067
Country 144870 0
Australia
Phone 144870 0
+61 407746299
Fax 144870 0
Email 144870 0
[email protected]
Contact person for public queries
Name 144871 0
Shaun O'Leary
Address 144871 0
School of Health and Rehabilitation Sciences, University of Queensland, Building 84a Therapies Annexe, QLD 4067
Country 144871 0
Australia
Phone 144871 0
+61 407746299
Fax 144871 0
Email 144871 0
[email protected]
Contact person for scientific queries
Name 144872 0
Shaun O'Leary
Address 144872 0
School of Health and Rehabilitation Sciences, University of Queensland, Building 84a Therapies Annexe, QLD 4067
Country 144872 0
Australia
Phone 144872 0
+61 407746299
Fax 144872 0
Email 144872 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.